Multiple Myeloma D009101

Related MeSH Hierarchy (6)

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Plasma Cell » Multiple Myeloma

Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Hemostatic Disorders » Multiple Myeloma

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Paraproteinemias » Multiple Myeloma

Description

A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.   MeSH

Subtype Terms (1)

Leukemia, Plasma Cell
44 drugs (34 approved, 10 experimental)


Phase 3 Indicated Drugs (102)

Phase 2 Indicated Drugs (310)

153sm-edtmp

18f-fluciclatide

18f-naf

23-valent pneumococcal polysaccharide vaccine (pneumovax-23)

89zr-dfo-daratumumab

90Yttrium-labelled Anti-CD66 Monoclonal Antibody

abatacept (orencia)

abemaciclib (verzenio)

acetic acid (vosol)

acetylcarnitine

activated marrow infiltrating lymphocytes

adavosertib

adenovirus type-5 vectored covid-19 vaccine

afatinib (gilotrif)

aflibercept (zaltrap)

aldesleukin (proleukin)

alemtuzumab (campath)

alisertib

allo-605

allo-647

allogeneic cord blood

allogeneic epstein-barr virus specific cytotoxic t-lymphocytes

allogeneic myeloma vaccine

allopurinol (zyloprim)

allostim

alpelisib (Piqray)

alt-801

alt-803

alvocidib

anakinra (kineret)

angiotensin 1-7

anti-minor histocompatibility complex (miha) donor t-lymphocytes

antineoplaston a10

apc8020

apo010

arsenic trioxide (trisenox)

at9283

atorvastatin (lipitor)

autologous-allogeneic tandem hematopoietic stem cell

autologous cd34+ cells

autologous dendritic cells electroporated with wt1 mrna

autologous epstein-barr virus-specific cytotoxic t lymphocytes

autologous ex-vivo expanded effector cells

autologous hematopoietic stem cells

autologous lymphocytes

autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine

autologous natural killer cells

autologous nk cells

autologous regulatory t cells

autologous t cells

autologous umbilical cord blood

auy922

avelumab (bavencio)

axitinib (inlyta)

azacitidine (vidaza)

azd4547

azd-4547

azd-5672

basiliximab (simulect)

bcma-pd1-cart cell

beclomethasone (vanceril)

belinostat (beleodaq)

beractant (survanta)

betathine

bevacizumab (avastin)

bf4

bgb-11417

bhq-880

bhq990

binimetinib (mektovi)

bkt-140

bleomycin (blenoxane)

bms-986016

bms-986207

bone marrow cells

bosutinib (bosulif)

brostallicin

bryostatin

Phase 1 Indicated Drugs (266)


Organization Involved with Phase 3 Indications (251)

Abbott

AbbVie

AB Science

Adaptive Biotechnologies

AEterna Zentaris

Agirov Klinik

Aronex Pharmaceuticals

Assistance Publique - Hôpitaux de Paris

Austrian Forum Against Cancer

Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista

Barts & The London NHS Trust

Baylor University

Belgian Hematological Society

Bengbu Medical College

BioLineRx, Ltd.

Blood and Marrow Transplant Clinical Trials Network

Cabyc, S.L.

Canadian Cancer Trials Group

Cancer and Leukemia Group B (CALGB)

Cancer Research UK

Cape Cod Healthcare

Case Western Reserve University

Center for International Blood and Marrow Transplant Research

Centocor

Central European Myeloma Study Group

Central Hospital of Kanta-Hame

Centre Henri Becquerel

Centre hospitalier de Mulhouse

Cephalon

Changshu First People's Hospital

CH Argenteuil

CH BAYONNE

CH DUNKERQUE

Christiana Hospital

CHR ORLEANS

Chugai

CHU Henri Mondor

CHU ST PRIEST EN JAREZ

City of Hope National Medical Center

ClinAssess GmbH

Clinica Universidad de Navarra

Complejo Hospitalario de Salamanca

Cornell University

Curie Institute

Daiichi Sankyo

Dalhousie University

Deutsche Studiengruppe Multiples Myelom

Duke University

Eastern Cooperative Oncology Group

Eastern Maine Medical Center

ECOG-ACRIN Cancer Research Group

Erasmus University Rotterdam

Erkim Ilac A.S.

European Group for Blood and Marrow Transplantation

European Myeloma Network

European Organisation for Research and Treatment of Cancer

European Union

Federal University of Bahia

Federal University of Rio de Janeiro

Fondazione Neoplasie Sangue Onlus

François Rabelais University

Freeman Health System

Friedrich Schiller University

Gazi University

Genentech

Genta

Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

GlaxoSmithKline

Government of France

Government of Netherlands

Government of Norway

Grupo Cooperativo de Hemopatías Malignas

Grupo de Estudos Multicentricos em Onco-Hematologia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Gruppo Italiano per lo Studio del Mieloma Multiplo

Guangzhou Medical University

Guthrie Clinic

Helse Forde

Helse Møre og Romsdal HF

Hoosier Cancer Research Network

Hospital Avicenne

Hospital Clinico Madrid

Hospital Doce de Octubre Madrid

Hospital Universitari Son Dureta

HOVON - Dutch Haemato-Oncology Association

Huai'an Second People's Hospital

Icahn School of Medicine at Mount Sinai

I-Mab Biopharma

Imperial College London

Institut Paoli-Calmettes

Intergroupe Francophone du Myelome

International Myeloma Foundation (IMF)

James R. Berenson MD, Inc.

Jiangnan University

Jiangyin People's Hospital

Jingjiang People's Hospital

Jinlin University

Johns Hopkins University

Julius-Maximilians University

Karyopharm Therapeutics Inc

Kiadis Pharma

King Faisal University

Kunming Medical University

Kuopio University Hospital

Laphal

Levanger Hospital

Ludwig Maximilians University

Marche Polytechnic University

Maria Sklodowska Curie Children's Hospital

Marshall University

Mayo Clinic

McMaster University

Medical College of Wisconsin

Medical Research Council

Medsearch

Metro-Minnesota

Molinette Hospital

Myeloma Institute for Research & Therapy

Nanjing Medical University

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)

National Marrow Donor Program

National University of Singapore

Newton-Wellesley Hospital

Nordic Cancer Union

Nordic Myeloma Study Group

Nordland Hospital

Northwell Health

Northwestern University

Norwegian University of Science and Technology

Ochsner Health System

Ohio State University

Oncopeptides AB

Oncotherapeutics

Oregon Health and Science University

Oslo Metropolitan University

Otsuka

Paris Diderot University

Pfizer

PharmaMar

Pierre Fabre

Poniard Pharmaceuticals

Prologue Research International

Radboud University

Region Syddanmark

Riverside Haematology Group

Roche

Royal Marsden Hospital NHS Trust

Russian Academy of Medical Sciences

Rutgers University

Seinajoki Central Hospital

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Simcere Pharmaceutical Co., Ltd

Sorlandet Hospital HF

Southern Medical University

Southwest Oncology Group

Stanford University

State University of New York, Brooklyn

State University of New York, Buffalo

St. Louis University

Sundsvall Hospital

Sykehuset Ostfold

Temple University

The Hospital of Vestfold

The University of Texas, Dallas

Tibotec

Turkish Society of Hematology

Universidad Autonoma de Madrid

Universidad Carlos III Madrid

Universidad Complutense de Madrid

Université de La Réunion

University Clermont Auvergne

University Hospital of North Norway

University of Alabama, Birmingham

University of Ankara

University of Antwerp

University of Arizona

University of Athens

University of Barcelona

University of Bergen

University of Bologna

University of Bonn

University of Bordeaux

University of Brescia

University of Burgundy

University of Caen-Normandie

University of California, Davis

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Cantabria

University of Chicago

University of Cologne

University of Franche-Comté

University of Glasgow

University of Grenoble

University of Groningen

University of Heidelberg

University of Helsinki

University of Jena

University of Lausanne

University of Leeds

University of Leipzig

University of Liege

University of Lille

University of Limoges

University of London

University of Lorraine

University of Lyon

University of Manitoba

University of Melbourne

University of Michigan

University of Minnesota

University of Mississippi

University of Montreal

University of Munster

University of Nantes

University of North Carolina at Chapel Hill

University of Oslo

University of Ottawa

University of Perugia

University of Picardie Jules Verne

University of Pisa

University of Pittsburgh

University of Poitiers

University of Reims

University of Rennes

University of Rochester

University of South Florida

University of Stavanger

University of Tampere

University of Texas at Houston

University of Toronto

University of Toulouse

University of Turku

University of Utah

University of Valencia

University of Versailles

University of Washington

University of Western Brittany

University of Western Ontario

Utrecht University

Vanderbilt University

Wake Forest University

Washington University in St. Louis

Wayne State University

West of Scotland Lymphoma Group

Wilhelminenspital der Stadt Wien

WiSP GmbH

Wuezburg University Hospital

Zhangjiagang First People's Hospital

Organization Involved with Phase 2 Indications (340)

Aalborg University

Academic and Community Cancer Research United

Academic Myeloma Consortium

Accelovance

Acerta Pharma

Adaptimmune

Adknoma Health Research

Aduro BioTech

Advent Health

Albert Schweitzer Ziekenhuis

Alexandra Hospital, Athens, Greece

Alexion

Alliance Foundation Trials

Altor Bioscience

American Cancer Society, Inc.

American Society of Clinical Oncology

AmpliMed Corporation

AnorMED

Antengene Corporation

AOI Pharmaceuticals, Inc.

Apogee Biotechnology Corporation

Arbeitsgemeinschaft medikamentoese Tumortherapie

Arch Oncology

Array BioPharma

Assign Clinical Research GmbH

Astellas

Astex Pharmaceuticals, Inc.

AstraZeneca

Attenuon

Autolus Limited

Azienda Ospedaliera di Bolzano

Azienda Ospedaliera Universitaria Senese

AZ Sint-Jan

Bayer

Beckloff Associates, Inc.

Bethanien hospital, Frankfurt

Big Ten Cancer Research Consortium

Biogen

Biohaven Pharmaceuticals Inc.

BioInvent International AB

Biokine Therapeutics Ltd

Biologics, Inc.

Bioscience, S.A.

Biotest Pharmaceuticals

Bloodwise

Boston University

British Columbia Cancer Agency

Brown University

Burzynski Research Institute

Callisto Pharmaceuticals

Cancer Biotherapy Research Group

CancerCare Manitoba

Cancer Treatment Centers of America

Cancer Trials Ireland

Cantonal Hospital of St. Gallen

Cardiff University

CARsgen Therapeutics, Ltd.

Cartesian Therapeutics

CASI Pharmaceuticals, Inc.

CellCentric Ltd.

Cellectar, Inc

Cell Genesys

Celularity, Inc.

Centre de Commercialisation en Immunothérapie du Cancer

Centre de Commercialisation en Immunothérapie du Cancer (C3i)

Centre Hospitalier de Blois -BLOIS

Centre Leon Berard

Chang Gung University

China Food and Drug Administration

Chipscreen Biosciences, Ltd.

Chongqing Medical University

Chongqing Precision Biotech Co., Ltd

Chonnam National University

Christian Medical College, Vellore, India

Chroma Therapeutics

Chu De Liège

CHU Mont-Godinne

Ciusss de L'Est de l'Île de Montréal

Clinical Service, China

Clinipace LTD

Colorado Blood Cancer Institute

Constant Pharmaceuticals

Criterium, Inc.

CTC Bio, Inc.

CTI BioPharma

CureTech Ltd

Cyteir Therapeutics, Inc.

Danish Myeloma Study Group

Dartmouth University

Department of Defense

Department of Veteran Affairs

Diverse Biotech

Dutch Cancer Society

Edwards Foundation, Inc.

Eisai

Eli Lilly

Enceladus Pharmaceuticals BV

Entera Health, Inc

European Commission

ExcellThera

Exelixis

Fondos ARI

Fondo Social La Caixa

Free University of Amsterdam

Free University of Brussels

Fudan University

Fundación Pública Andaluza

Gachon University

Gateway for Cancer Research

Genenta Science S.R.L.

Gennimatas Hospital, Athens

GenScript

German Cancer Research Center

German Research Foundation

Geron Corporation

Ghent University

Gilead Sciences

Gleneagles CRC

Gleneagles Hospital, Singapore

GlycoMimetics, Inc.

Government of Canada

Government of Finland

Government of Japan

Government of Singapore

Gruppo Italiano Studio Linfomi

GWT-TUD GmbH

Hackensack University Medical Center

Harpoon Therapeutics

HeaDS

Healogics

Hebrew University

Heidelberg Clinical Research Centre

Hellenic Society of Hematology

Helsinn

Henan Medical University

Herbert Irving Comprehensive Cancer Center

Hoag Memorial Hospital Presbyterian

HOANNJ-Carol G. Simon Cancer Center

Horizon Health Network

Hospital Universitario Reina Sofía

Huazhong University of Science and Technology

Human Genome Sciences

Immune Control

Immunomedics

Immunovative Therapies

Incyte

Indiana University

Innate Pharma

Institut de Cancerologie de l'Ouest Paul Papin

Institut d'Investigacions Biomèdiques August Pi i Sunyer

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

International Myeloma Foundation

inVentiv

IO Biotech

IQVIA

Isala Clinics, Zwolle, The Netherlands

Italfarmaco

James Berenson Inc.

James Graham Brown Cancer Center

Jilin University

Juno Therapeutics, Inc.

Kantonsspital Graubünden

Kaohsiung Medical University

Karolinska Institute

Katholieke Universiteit Leuven

KCAS Bio

Kleo Pharmaceuticals

Korean Multiple Myeloma Working Party

Korea Research Institute of Bioscience & Biotechnology

Kosin University

Kyowa Hakko Kirin

Leo Pharma

LifeTime Pharmaceuticals

Loyola University

Ludwig Institute for Cancer Research

Luzerner Kantonsspital

Maastricht University

Mater Misericordiae University Hospital

Meander Medical Center

Medac

Medical Prognosis Institute A/S

Memorial Sloan-Kettering Cancer Center

Merck KGaA

Methodist Cancer Center, Houston, Texas

Mikkeli Central Hospital

Minnesota Medical Foundation

Molecular Partners AG

MolMed S.p.A.

Monash University

Moorgreen Hospital, Southampton

MorphoSys

Multiple Myeloma Research Consortium

Multiple Myeloma Research Foundation

Mundipharma

Myeloma Canada Research Network

Myeloma UK

Nagoya City University

Nanyang Technological University

National Health Service, United Kingdom

National Institutes of Health (NIH)

National Taiwan University

Nerviano Medical Sciences

Netherlands Cancer Institute

New York Medical College

New York University

NexImmune Inc.

Nij Smellinghe Hospital Drachten

Northside Hospital, Inc.

Norwood Immunology Limited

Noxxon AG

OHSU Knight Cancer Institute

Oncoceutics, Inc.

Oncology Venture

OncoPep, Inc.

Onkozentrum Zürich

Onxeo

Ortho Biotech, Inc.

Our Lady of Mercy Medical Center

Parke-Davis

Pavlov First Saint Petersburg State Medical University

Pennsylvania State University

Peter MacCallum Cancer Centre

Pharmacyclics

Piramal

Polish Myeloma Consortium

Polyphor Ltd.

Precision BioSciences, Inc.

Precision Medicine

PrECOG, LLC.

Prolexys Pharmaceuticals

Queen's University, Belfast

Rapa Therapeutics LLC

RedHill Biopharma

Regeneron

Rhode Island Hospital

RIEMSER Arzneimittel GmbH

Rijnstate Hospital

RWTH Aachen University

Scios

SCRI Development Innovations

Seoul National University

Sevion Therapeutics

Shanghai Asclepius Meditec Inc.

Shenzhen BinDeBio Ltd.

Shenzhen Geno-Immune Medical Institute

Singapore General Hospital

Sirtris Pharmaceuticals

Situs Cancer Research Center

Smerud Medical Research Denmark

SmithKline Beecham

Sparrow Regional Cancer Center

Spectrum Pharmaceuticals

Sponsor GmbH

State University of New York, Syracuse

Stemline Therapeutics, Inc.

Stony Brook University

Sungkyunkwan University

Swiss Group for Clinical Cancer Research

SymBio Pharmaceuticals

Symphony Capital

TaiGen Biotechnology Co., Ltd.

Taipei Veteran General hospital

Tata Memorial Hospital

Technion University

Tel Aviv University

Telik

Teva

Texas Oncology Cancer Center

Texas Transplant Institute

TFS Trial Form Support

The Australasian Leukaemia & Lymphoma Group (ALLG)

The Beijing Pregene Science and Technology Company, Ltd.

The Leukemia and Lymphoma Society

Theradex

The University of Hong Kong

The Wayne D. Kuni and Joan E. Kuni Foundation

Thomas Jefferson University

Threshold Pharmaceuticals

Titan Pharmaceuticals

Trevie, Inc.

Trinity Health of New England

Triphase Research and Development Corporation

Tufts University

Tzu Chi University

Unicorn Pacific Corporation

Universidad de Cordoba

Universitair Ziekenhuis Gent

University of Alberta

University of Amsterdam

University of Applied Sciences Würzburg-Schweinfurt

University of Bern

University of Birmingham

University of British Columbia

University of Cagliari

University of Calgary

University of California, Berkeley

University of Campinas

University of Colorado, Denver

University of Connecticut

University of Copenhagen

University of Duisburg-Essen

University of Erlangen-Nuremberg

University of Freiburg

University of Hamburg

University of Iceland

University of Iowa

University of Kansas

University of Louisville

University of Maryland, Baltimore County

University of Medicine and Dentistry of New Jersey

University of Miami

University of Nebraska

University of Oxford

University of Patras

University of Pennsylvania

University of Regensburg

University of Roma La Sapienza

University of Salamanca

University of Seville

University of Southern California

University of Tennessee

University of Torino

University of Tuebingen

University of Ulsan

University of Virginia

University of Warwick

University of Wisconsin

Vaxil Therapeutics Ltd.

Virginia Commonwealth University

Vita-Salute University of Milano. Italy

Vivolux AB

Wilheminenspital

Wyeth

Xcyte Therapies

Yale University

Yeshiva University

Yonsei University

Zhengzhou University

Ziopharm

ZNA Antwerpen

Organization Involved with Phase 1 Indications (124)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.